Michael Burry, best known for predicting the 2008 housing market crash and being featured in The Big Short, continues to attract attention with his highly concentrated and contrarian investment approach.
His fund, Scion Asset Management, isn’t known for holding dozens of positions across sectors. Instead, Burry focuses on a small number of high-conviction bets. As of the second quarter of 2025, his portfolio held just six stocks with a total value of about $56.25 million. The composition strongly emphasizes consumer and healthcare companies, highlighting his defensive leanings and willingness to buy quality names under pressure. Here are Michael Burry’s top current stock picks as of the second quarter of 2025, according to his 13F filing:
1. Michael Burry’s Investing Style and Q2 2025 Portfolio Overview
Burry’s portfolio as of June 30, 2025, reflects his preference for concentration. Six positions comprise the entire fund, and two alone account for more than forty percent of its total value. This type of focused investing is a hallmark of his strategy. While many managers spread risk across dozens of names, Burry doubles down on fewer companies where he sees significant upside potential relative to risk.
This quarter, the portfolio mix tilts toward consumer goods and healthcare, two areas that often provide resilience in uncertain markets. His willingness to take sizable positions in companies that have recently fallen out of favor shows that he hasn’t abandoned his contrarian instincts.
2. Estee Lauder: Burry’s Largest Position Despite a Trim
Burry’s largest holding is Estee Lauder, which makes up 21.55 percent of his fund, with 150,000 shares valued at roughly $12.1 million. He trimmed this position by 25 percent during the quarter, which signals partial profit-taking but not a lack of conviction. The reported purchase price was $80.80, and the stock had risen to $90.74 by the end of the reporting period, marking a gain of more than 12 percent.
Estee Lauder’s stock has seen wide swings over the past year, ranging from $48.12 to $101.93. The company has been working through the aftereffects of weaker demand in China and pandemic-driven disruptions, but its global brand strength remains undeniable. Burry keeps it as a core holding while managing exposure after a strong rebound.
3. Lululemon: A Contrarian Bet on Premium Apparel
His second-largest position is Lululemon, accounting for 21.12 percent of the portfolio. Burry purchased 50,000 shares at an average reported price of $237.58, yet the stock stood at $203.62 by the filing date, down more than 14 percent. Its 52-week range stretched from $185.95 to $423.32, highlighting the volatility in its share price.
Lululemon has faced headwinds as growth slowed, and investors have questioned whether premium athletic apparel can maintain the same momentum as in past years. For many managers, these concerns would be a reason to exit. For Burry, they appear to be a reason to buy. His move suggests he sees long-term brand strength and international expansion opportunities that could outlast short-term earnings pressures.
4. Bruker Corporation: Value Play in Scientific Instruments
Bruker Corporation represents 18.31 percent of the portfolio. Burry bought 250,000 shares at $41.20, yet the price had dropped to $34.24 by the reporting date, leaving him with a paper loss of almost 17 percent. The stock’s 52-week range runs from $30.00 to $72.70, showing its volatility.
Bruker specializes in scientific instruments and laboratory technology, a sector that doesn’t usually make headlines but plays a crucial role in advancing research and healthcare. Its decline since Burry’s entry is consistent with his stepping into companies when market sentiment is weak. The purchase fits neatly into his strategy of scooping up undervalued assets with long-term relevance.
5. Regeneron Pharmaceuticals: A Biotech Winner in the Portfolio
Regeneron makes up 14 percent of Burry’s holdings and has been one of his more successful recent purchases. He owns 15,000 shares acquired at $525 each, with the stock climbing to $573.91 by the filing date for a gain of over 9 percent. Regeneron’s price has fluctuated from $475.76 to as high as $1,206.03 in the past year, reflecting the volatility of biotech and the company’s strong position in the industry.
The company is best known for developing ophthalmology, oncology, and immunology treatments. Regeneron continues to generate substantial revenue and has a strong pipeline, which may have attracted Burry to the stock. Unlike some of his other positions, this one is firmly in positive territory, giving his portfolio a boost from healthcare innovation.
6. MercadoLibre: The Amazon of Latin America
MercadoLibre, often described as the Amazon of Latin America, makes up 13.94 percent of the portfolio. Burry owns 3,000 shares purchased at an average of $2,613.67. By the filing date, the stock had fallen to $2,364.01, representing a decline of nearly 10 percent. Its 52-week trading range runs from $1,646 to $2,645.22.
MercadoLibre operates e-commerce and digital payments businesses across Latin America, giving it dual exposure to two massive growth markets. While the stock has dipped since Burry bought it, its long-term story remains compelling. Its position in online retail and fintech makes it one of the most dominant companies in the region, and Burry’s investment suggests he believes its future growth will outweigh current volatility.
7. UnitedHealth Group: Defensive Strength in Healthcare
UnitedHealth Group rounds out the portfolio at 11.09 percent. Burry purchased 20,000 shares at an average of $311.95, and the stock was trading at $308.49 at the time of reporting, just slightly below his entry price. The range for the year has been between $234.60 and $621.24, highlighting both its potential and its sensitivity to broader healthcare sector moves.
As the largest healthcare insurer in the U.S., UnitedHealth provides a strong defensive anchor in Burry’s portfolio. It generates consistent cash flow, benefits from scale, and operates in a steady-demand sector. By combining UnitedHealth with Regeneron and Bruker, Burry has built a significant healthcare exposure that balances growth and stability.
Conclusion: What Burry’s 2025 Picks Reveal About His Strategy
Michael Burry’s portfolio in mid-2025 shows just how deliberate and contrarian his investing style continues to be. With only six stocks making up his entire fund, each position reflects conviction and careful selection.
His two most significant holdings, Estee Lauder and Lululemon, are consumer names facing challenges but backed by global brands. Bruker and MercadoLibre add contrarian elements in scientific instruments and Latin American growth markets. Regeneron provides exposure to biotechnology innovation, while UnitedHealth adds a defensive layer in U.S. healthcare.
These choices show that Burry isn’t chasing the latest market trend. Instead, he’s focusing on sectors with long-term value, even if they face near-term headwinds. His 2025 picks highlight a balance between recovery opportunities and defensive stability while staying true to the concentrated, high-conviction style that made him one of the most closely watched investors today.